A jury dealt Bayer AG a third justice defeat, awarding $2.055 billion to a California integrate who blamed a German company’s Roundup weedkiller for causing their cancer.
The outcome by a Northern California jury comes as Bayer
BAYRY, -2.76%
faces a rebel from shareholders over final year’s merger of Monsanto Co., that unprotected Bayer to some 13,400 claims restraining Roundup to cancer.
Two prior hearing waste have helped clean some-more than 30% off Bayer’s share price. Last month, a infancy of Bayer shareholders refused to validate management’s actions in a past year, indicating that investors miss certainty in how a association is being run.
Bayer has appealed a $78.5 million outcome reached in August, a initial Roundup box to go to trial. It has pronounced it would interest a second, a some-more than $80 million jury endowment motionless in March.
Some investors have pushed Bayer to settle a cases soon, yet companies confronting product-liability claims mostly move a dozen or some-more cases to hearing before severely entering allotment talks.
Reaching a allotment in a box is difficult by a fact that a product continues to be sole to consumers and farmers and doesn’t lift a cancer-warning label, that means a intensity pool of plaintiffs could enhance indefinitely. The association could strech a understanding with a stream collection of plaintiffs and set aside income to compensate out destiny claims, or continue fighting box by box to accumulate some-more information points. People informed with Bayer contend a association isn’t formulation to settle before during slightest a initial few cases have left by appeal.
An stretched chronicle of this news appears during WSJ.com.
We Want to
Hear from You
Join a conversation
